Riskpilot← Back to searchSign inGet full accessPOA Pharma Scandinavia AB
ABActiveOrg 5567497507Ebbe Lieberathsgatan 21Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20088 employees
Revenue 2024
SEK 103,7M
+9% vs 2023
EBITDA margin
0.6%
-74% vs 2023
Equity ratio
47.0%
Financial strength
Net profit 2024
SEK -965K
-288% vs 2023
| Revenue | SEK 103,7M | +9% |
| EBITDA | SEK 652K | -74% |
| Net profit | SEK -965K | -288% |
| Total assets | SEK 55,6M | +5% |
| Equity | SEK 26,2M | -4% |
| Employees | 8 | — |
Legal name
POA Pharma Scandinavia AB
Org number
5567497507
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 januari 2008
Share capital
SEK 100 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva handel, marknadsföring, distribution och utveckling av produkter inom läkemedel och hälso- och sjukvård samt därmed förenlig verksamhet. Bolaget ska även ha som verksamhet att äga och förvalta fast och lös egendom.
Address
Ebbe Lieberathsgatan 21
Phone
+46317880599
Email
info@poaab.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 47 459 | 78 696 | 84 812 | 95 311 | 103 709 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 3 174 | −1 866 | 4 869 | 2 478 | 652 |
| Depreciation & amort. | −304 | −616 | −906 | −866 | −857 |
| EBIT | 2 870 | −2 482 | 3 963 | 1 612 | −205 |
| Net financials | −1 690 | −9 | −23 | −132 | −543 |
| Profit before tax | 1 180 | −2 491 | 3 940 | 1 480 | −747 |
| Tax | −548 | −0 | −496 | −968 | −218 |
| Net profit | 632 | −2 491 | 3 444 | 512 | −965 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 35 557 | 36 609 | 40 798 | 52 810 | 55 627 |
| Equity | 25 654 | 23 163 | 26 607 | 27 119 | 26 154 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 9 903 | 13 446 | 14 191 | 25 691 | 29 473 |
| Total debt | 9 903 | 13 446 | 14 191 | 25 691 | 29 473 |
EBITDA margin
0.6%
This company
15.8%
Market median
-96% vs market
20202024
Equity ratio
47.0%
This company
38.2%
Market median
+23% vs market
20202024
Return on equity
-3.7%
This company
18.4%
Market median
-120% vs market
20202024
Net profit margin
-0.9%
This company
8.1%
Market median
-111% vs market
20202024
Asset turnover
1.86×
This company
1.12×
Market median
+66% vs market
20202024
Debt / equity
1.13×
This company
0.62×
Market median
-82% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-09-30
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
DB Chief Executive Officer | Chief Executive Officer | 2021 |
EM Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
ES Chief Auditor | Chief Auditor | 2024 |
| Former (3) | ||
VH Authorized Recipient of Service | Authorized Recipient of Service | 2021 – 2022 |
LP Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2022 |
ÅC Chief Auditor | Chief Auditor | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Former (2) | ||
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2021 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GALEN LTD
POA Pharma Scandinavia AB (this company)Poa Pharma GmbhPOA PHARMA GMBHBoard members of POA Pharma Scandinavia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dennise Broderick | Chief Executive Officer | 0 companies |
| Valdet Hetemi | Authorized Recipient of Service | 0 companies |
| Lars Pontus Söderlind | Authorized Recipient of Service | 0 companies |
| Emma Maria Johanna Sjögren | Authorized Recipient of Service | 0 companies |
| Åsa Cecilia Önfelt | Chief Auditor | 0 companies |
| Emma Sofia Maria Andersson | Chief Auditor | 0 companies |
| Graeme Thomas McBurney | Board of Directors | 0 companies |
| Niall Patrick Harkin | Board of Directors | 0 companies |
| Colin Hayburn | Board of Directors | 0 companies |
| William Stephen Campbell | Board of Directors | 0 companies |
| Alan David Armstrong | Chairman | 0 companies |